Genomics in Precision Oncology Xchange
Europe, Munich
June 28, 2022
Welcome to hubXchange’s European Genomics in Precision Oncology 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in genomics-led oncology precision medicine strategies.
Discussion topics will cover Cancer Genomics, Translational Bioinformatics, Data Quality & Access, Genomics Informed Clinical Decisions and Precision Oncology.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
This will be an In-Person meeting with a hybrid option to join virtually.
Venue Details: Hilton City Munich, Rosenheimer Strasse 15, Munich
Cancer Genomics
Opening Address & Keynote:
Getting de-centralized testing into routine clinical oncology using high-performance genetic multiplexing
- The need for accessible, easy-to-use technology that deploys seamlessly across labs in the liquid biopsy space
- Assay standardization democratizes this tool for the absolute quantification of ctDNA, supporting the practical clinical development of biomarkers
- Fast turnaround times, higher multiplexing, and increased sensitivity – all without the need for outsourcing of samples – can bring uncompromised real-time oncology diagnostics and monitoring to patients
Co-Founder, Stilla Technologies
With 10 year experience in the Life Science sector, Clément Gay co-founded Stilla Technologies. He is directing business & corporate development activities with the goal of establishing partnerships with Biopharmas & CROs to develop content (CDx, IVD kits etc.)on the naica digital PCR system . Clément graduated from HEC Paris, with a Master Degree in Business & Entrepreneurship.
Better informing treatment options
- How to enable oncologists to get faster decisions using molecular testing
- How do we better support the practical clinical development of biomarkers
- Identifying and measuring personalized mutations in the patient monitoring setting
Co-Founder, Stilla Technologies
With 10 year experience in the Life Science sector, Clément Gay co-founded Stilla Technologies. He is directing business & corporate development activities with the goal of establishing partnerships with Biopharmas & CROs to develop content (CDx, IVD kits etc.)on the naica digital PCR system . Clément graduated from HEC Paris, with a Master Degree in Business & Entrepreneurship.
Spotlight Presentation: Unlocking the complexity of tumor heterogeneity with multiplex imaging and spatial phenomics.
- Why spatial relationships are important in tumor biology
- Examine specific cell clustering, dispersion, and co-localization
- Identify immune rich and excluded regions and better inform your trial design.
- To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.
Senior Director Molecular and Computational Pathology, Ultivue
As a Senior Director, Molecular and Computational Pathology at UV Sotirios is responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. Sotirios is a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics. He also holds a Master´s degree in Web Science from the Dep. Of Mathematics, Aristotle University.
Sotirios started his career in 2011 at the Laboratory of Molecular Oncology in Thessaloniki, Greece where he laid the foundations of his expertise in translational science and molecular diagnostic techniques, studying the genotypic and phenotypic heterogeneity of the major cancer types.
Since 2014, he has been part of cross-disciplinary industry efforts to establish and validate novel diagnostic and translational pathology workflows, develop precision biomarker concepts, and commercialize oncology diagnostic devices such the MammaTyper® (BioNTech Dx) and the NEOLiquid assays (NEO New Oncology).
In 2018 Sotirios joined Definiens/Computational Pathology AstraZeneca, to build an integrated pathology informatics team with the goal to enable advanced tissue-informed decision-making in oncology drug development programs, by delivering state-of-the-art pathology data for the training and verification of machine learning algorithms.
4:10 – 4:40pm
Poster Session: Single-Cell DNAseq to Advance Oncology Research
- Unravel tumor heterogeneity, reconstruct phylogenetic trees, and discern early driver gene alterations
- Improve patient stratification distinguishing responders from non-responders
- Reveal therapy resistance mechanisms through course of treatment
- Monitor patients for minimal residual disease (MRD) with high sensitivity of single-cell analysis
- Identify better therapies and guide adaptive/rational combination therapies
Technical Application Liaison, Mission Bio
Simone Formisano is Technical Application Liaison at Mission Bio. He obtained his Master’s Degree in Biotechnology at Columbia University, New York City (United States). Before joining Mission Bio in 2022, Simone completed his Doctorate experimental work in cancer immunotherapy at
Ludwig Maximilian University of Munich. Afterward, he contributed to the clinical development of several therapies in solid oncology by joining Daiichi Sankyo as a Medical Science Liaison.
